Arecor Limited will tomorrow present the successful results of a clinical trial of its ultra-rapid acting insulin formulation at a prestigious industry conference.
The biopharmaceutical company’s phase-one study compared the pharmacokinetics (PK), pharmacodynamics (PD) and safety of its AT247 insulin formulation in comparison to insulin aspart, NovoRapid, and fast insulin aspart, Fiasphas.
A report of the trial has been selected for oral presentation at the upcoming European Association for the Study of Diabetes (EASD) virtual meeting on Tuesday, September 22 at 1.30pm UK time.
AT247 is an investigational novel meal-time insulin formulation that aims to significantly accelerate insulin absorption, post injection, to enable more effective management of blood glucose levels.
It has been designed to move through the body, shown via rates of PK and PD, in a way that more closely matches the physiological insulin mealtime response of a person without diabetes.
“Presenting the successful results of our Phase 1 study of AT247 at EASD demonstrates the clear potential for our ultra-rapid acting insulin,” said Arecor’s chief executive officer, Sarah Howell.
“We believe that AT247’s superior profile will improve both treatment and healthcare outcomes for people living with Type 1 diabetes.
“As treatment delivery systems continue to evolve, we believe that AT247’s favourable profile over current treatments may play a pivotal role in advancing the delivery of care, with the potential to enable the artificial pancreas, which could significantly reduce the burden of self-management for people living with diabetes.”